STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
09 juil. 2024 07h00 HE
|
STALICLA
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9,...
Transforming Children's Lives: DP World's Aviv Clinics Dubai’s Revolutionary Youth Protocol
07 juil. 2024 21h00 HE
|
Aviv Clinics
DUBAI, United Arab Emirates, July 07, 2024 (GLOBE NEWSWIRE) -- At DP World's Aviv Clinics Dubai, the world’s most advanced brain and body performance clinic, we understand the heartache parents feel...
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
27 juin 2024 07h10 HE
|
STALICLA
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core...
Catalight Practice Guidelines Reflect a Contemporary Research View of the Dosage Effect and Outcome Measures in Autism Care
23 avr. 2024 17h28 HE
|
Catalight
WALNUT CREEK, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Catalight, one of the largest behavioral health networks in the United States working to support individuals with autism and intellectual and...
Huntington Bancshares Incorporated Hires Three Neurodiverse Teams Fulltime in Technology with CAI Neurodiverse Solutions
17 avr. 2024 09h00 HE
|
CAI
CAI today announced that Huntington Bank hired three teams of neurodivergent individuals fulltime through CAI Neurodiverse Solutions.
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
11 avr. 2024 16h30 HE
|
PaxMedica, Inc.
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
13 mars 2024 08h20 HE
|
PaxMedica, Inc.
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
BlueSprig Pediatrics Sponsors Armani Williams Ahead of the Daytona ARCA 200
12 févr. 2024 09h00 HE
|
BlueSprig Pediatrics, Inc.
DAYTONA BEACH, Fla., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Blue Sprig Pediatrics, Inc. (BlueSprig), a leader in Applied Behavior Analysis (ABA) therapy for children diagnosed with Autism Spectrum...
Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements
16 janv. 2024 06h00 HE
|
STALICLA
Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the...
Xolv Creates a New Venture to Embark on New Era of Innovation in Behavioral Health
03 janv. 2024 16h53 HE
|
Xolv
WALNUT CREEK, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xolv, formerly Catalight’s IT and technology innovation group, proudly announces its transition to a new corporation today as part of a...